A novel photodynamic therapy for drug-resistant prostate cancer cells using porphyrus envelope as a novel photosensitizer

Photodiagnosis and Photodynamic Therapy

Volumn 11, Issue 1, 2014, Pages 48-54

  Yamauchi, Masaya ^a   Honda, Norihiro ^a   Hazama, Hisanao ^a   Tachikawa, Shoji ^b   Nakamura, Hiroyuki ^b   Kaneda, Yasufumi ^c   Awazu, Kunio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b GAKUSHUIN UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug delivery system; Drug resistance; Hemagglutinating virus of Japan envelope; Photodynamic therapy; Prostate cancer

Indexed keywords

AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT; PORPHYRUS ENVELOPE; PROTOPORPHYRIN; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CENTRIFUGATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PARAINFLUENZA VIRUS 1; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS ENVELOPE; PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; SENDAI VIRUS; TUMOR CELL LINE;

SENDAI VIRUS;

AMINOLEVULINIC ACID; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; PROTOPORPHYRINS; SENDAI VIRUS;

EID: 84895918251     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2013.10.001     Document Type: Article

References (20)

1. Claire C., Sweta R., Keith OB, Amanda O.N., Maria P., Rizwan S., et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE 2012, 7(12):e50999.
2. Koivisto P., Visakorpi T., Kallioniemi O.P. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest 1996, 56:57-64.
3. Klotz L.H., Herr H.W., Morse M.J., Whitmore W.F. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986, 58(11):2546-2550.
4. The interview form of Taxotere® (docetaxel for injection, Sanofi-Aventis). Pharmaceuticals and Medical Devices Agency (PMDA). http://www.info.pmda.go.jp/go/interview/1/780069_4240405A1037_1_011_1F.
5. Schuitmaker J.J., Baas P., van Leengoed H.L., van der Meulen F.W., Star W.M., van Zandwijk N. Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B 1996, 34(1):3-12.
6. Charles J.L., Stephen K.H., Norman E.M., James S.M., Hans G., Bergein F.O., et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995, 42(6):507-512.
7. Zhang Q., Li Y., Shi Y., Zhang Y. HVJ envelope vector, a versatile delivery system: its development, application, and perspectives. Biochem Biophys Res Commun 2008, 373(3):345-349.
8. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key, role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41(1):189-207.
9. Mima H., Yamamoto S., Ito M., Tomoshige R., Tabata Y., Tamai K., et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006, 5(4):1021-1028.
10. Mima H., Tomoshige R., Kanamori T., Tabata Y., Yamamoto S., Ito S., et al. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 2005, 7(7):888-897.
11. Shimbo T., Kawachi M., Saga K., Fujita H., Yamazaki T., Tamai K., et al. Development of a transferrin receptor-targeting HVJ-E vector. Biochem Biophys Res Commun 2007, 364(3):423-428.
12. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol 1993, 221:18-41.
13. Kondo Y., Fushikida K., Fujieda T., Sakai K., Miyata K., Kato F., et al. Efficient delivery of antibody into living cells using a novel HVJ envelope vector system. J Immunol Methods 2008, 332(1-2):10-17.
14. Suzuki H., Kurooka M., Hiroaki Y., Fujiyoshi Y., Kaneda Y. Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett 2008, 582(9):1325-1329.
15. Kurooka M., Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007, 67(1):227-236.
16. Nakajima T., Itai T., Wada H., Yamauchi T., Kiyohara E., Kaneda Y. A novel therapy for melanoma and prostate cancer using a non-replicating sendai virus particle (HVJ-E). Novel gene therapy approaches 2013, InTech. M. Wei, D. Good (Eds.).
17. Nakamura H, El-Zaria ME, Ban HS, Japan Patent Kokai 2011-037748 (Feb 24, 2011).
18. Kennedya James C., Pottierb Roy H. New trends in photobiology: endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992, 14(4):275-292.
19. El-Zaria M.E., Ban H.S., Nakamura H. Boron-containing protoporphyrin IX derivatives and their modification for boron neutron capture therapy: synthesis, characterization, and comparative in vitro toxicity evaluation. Chem Eur J 2010, 16(5):1543-1552.
20. Honda N., Kariyama Y., Inoue T., Abe C., Inoue K., Ishizuka M., et al. Optical properties of tumor tissues grown on the chorioallantoic membrane of chicken eggs measured with a double integrating sphere and inverse Monte Carlo method in the wavelength range of 350-1000 nm. Proc SPIE 2013, 8579:85790T.